An innovative and potentially groundbreaking breast cancer vaccine has shown promising results in early trials, offering hope for the eradication of one of the world’s deadliest diseases. Fifteen women with an aggressive form of breast cancer have received the vaccine and have remained in remission for up to five years, despite being at high risk of relapse. Among them is Jennifer Davis, a 46-year-old nurse from Ohio, who underwent grueling rounds of chemo, radiotherapy, and a double mastectomy. She now expresses feeling physically and mentally better than ever before and hopes that everyone she knows can benefit from the vaccine.
The vaccine works by training the body to attack a protein that is present during pregnancy and breastfeeding but is also associated with the development of cancer. Currently, the vaccine is being tested on triple-negative breast cancer, a highly treatable but fast-spreading and often silent form of the disease. The goal is to eventually administer the vaccine to healthy individuals as a preventive measure against all forms of breast cancer, making it the first vaccine of its kind. Dr. Amit Kumar, CEO of Anixa Biosciences, the company behind the vaccine’s development, envisions the possibility of eliminating breast cancer as a disease altogether, similar to the eradication of polio and smallpox.
Researchers at the Cleveland Clinic in Ohio are cautiously optimistic about the trial results. Statistically, 40% of the women in the trial would be expected to experience cancer recurrence within five years, but so far, none have. Dr. Thaddeus Stappenbeck, chair of inflammation and immunity at Cleveland Clinic, describes the trial data as “very encouraging” and believes that within seven years, all forms of breast cancer could be effectively treated with the vaccine. The vaccine is administered in three doses, two weeks apart, and targets a protein called α-lactalbumin, which is found in the majority of triple-negative breast cancers. The vaccine aims to activate the immune system to destroy cancer cells that produce this protein, preventing them from growing into tumors.
The progress of the vaccine is the result of over 20 years of research by the late Dr. Tuohy, a renowned breast cancer scientist. The Cleveland Clinic is also making progress in developing an ovarian cancer vaccine using a similar approach. Triple-negative breast cancer is particularly challenging to treat as it lacks the receptors necessary for hormone therapy or targeted drugs to be effective. Approximately 40% of individuals with stage one to three triple-negative breast cancer experience a recurrence of the disease within five years after treatment.
The vaccine trial participants had to be tumor-free but at high risk of recurrence. None of the women in the trial have experienced cancer recurrence so far, providing hope that this disease can be conquered. Jennifer Davis, the first woman to receive the vaccine, discovered a lump in her breast in 2018 and was later diagnosed with triple-negative breast cancer. She underwent extensive treatment and sought a second opinion from the Cleveland Clinic, where she learned about the vaccine and enrolled in the trial. She received the three doses of the vaccine in 2021 and experienced no side effects aside from minimal lumps at the injection site.
The vaccine’s potential to prevent breast cancer and provide long-term remission is a remarkable development in the field of cancer research. With further advancements and research, it is hoped that this vaccine can revolutionize cancer treatment and improve outcomes for patients worldwide.
Denial of responsibility! VigourTimes is an automatic aggregator of Global media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, and all materials to their authors. For any complaint, please reach us at – [email protected]. We will take necessary action within 24 hours.
